Nanovibronix, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
ENvue Medical, Inc. is holding a special meeting of stockholders on August 14, 2026, to vote on a proposal to effect a reverse stock split of its common stock, ranging from 1-for-2 to 1-for-50, to regain compliance with Nasdaq's minimum bid price requirement.
NanoVibronix calls 2025 Annual Meeting for votes on board, auditor, incentive plan, and private placement share issuance.
NanoVibronix, Inc. filed a supplement to its definitive proxy statement to correct an inadvertent error regarding the number of outstanding Series G and Series X Preferred Stock shares ahead of its Special Meeting on July 11, 2025.
DEF: NanoVibronix Seeks Shareholder Approval for Second Reverse Stock Split to Avert Nasdaq Delisting
NanoVibronix, Inc. is calling a Special Meeting of Stockholders on July 11, 2025, to vote on a proposed reverse stock split, ranging from 1-for-2 to 1-for-50, aimed at increasing its per share price to maintain Nasdaq listing compliance.
NanoVibronix is holding a special meeting to seek stockholder approval for a reverse stock split and the issuance of shares related to a warrant exchange, aiming to maintain its Nasdaq listing.
NanoVibronix, Inc. has filed a definitive proxy statement with the SEC.
NanoVibronix, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on December 19, 2024, featuring proposals including director elections, auditor ratification, and approval of a long-term incentive plan.